SANDRA GOFINET PASOTO

(Fonte: Lattes)
Índice h a partir de 2011
22
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Revista / Livro: Jcr-Journal of Clinical Rheumatology ×

Resultados de Busca

Agora exibindo 1 - 10 de 11
  • article 2 Citação(ões) na Scopus
    Anti-DNase I Antibody A New Serological Reactivity in Primary Sjogren Syndrome
    (2020) GRIFFO, Priscilla; VIANA, Vilma V. S. T.; PASOTO, Sandra G.; LEON, Elaine P.; BONFA, Eloisa
    Background and Objective: Primary Sjogren syndrome (pSS) is a systemic autoimmune rheumatic disease that particularly affects exocrine glands. Dry eye is one of the most important features of this syndrome, and a recent study reported reduced deoxyribonuclease I (DNase I) activity in the tear of patients with dry eye. We therefore postulated that patients with pSS might have antibodies targeting DNAse I. Methods: We have evaluated in a cross-sectional study 85 patients with pSS (2002 American-European Consensus Group Criteria), 50 rheumatoid arthritis (RA) patients (1987 American College of Rheumatology Criteria) without sicca symptoms, and 88 healthy volunteers. IgG anti-DNase I was detected by enzyme-linked immunosorbent assay using as antigen bovine pancreas enzyme and confirmed by immunoblotting. Results: Age and sex were alike in the 3 groups (p > 0.05). Anti-DNase I was detected in 43.5% of the pSS patients. In contrast, this reactivity was absent in all RA patients (p = 0.0001). Additional comparison of pSS patients with (n = 37) or without (n = 48) anti-DNase I showed that the former group had higher IgG serum levels (2293.2 +/- 666.2 vs 1483.9 +/- 384.6 mg/dL, p = 0.0001) and greater rate of non-drug-induced leukopenia (43% vs 19%, p = 0.02). A multivariate logistic regression analysis identified that only IgG levels were independently associated with anti-DNase I. Conclusions: We describe a high frequency of anti-DNase I antibodies in pSS patients associated with higher serum IgG levels. The lack of this reactivity in RA patients without sicca symptoms suggests that this antibody may be helpful in the differential diagnosis of these diseases.
  • conferenceObject
    PERIPHERAL NERVOUS SYSTEM DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS: THE ROLE OF PREDISPOSING CONDITIONS
    (2018) FARGETTI, S.; BONFA, E.; SHINJO, S. K.; PASOTO, S. G.; SEGURO, L. P. C.; LOPES, M. R. U.; GONCALVES, C. R.; BORBA, E. F.
  • conferenceObject
    HOW ETHNICITY MODIFIES SYSTEMIC ACTIVITY OF PRIMARY SJOGREN SYNDROME: ANALYSIS OF BASELINE ESSDAI SCORES IN A MULTI-ETHNIC INTERNATIONAL COHORT
    (2018) RETAMOZO, Soledad; HERNANDEZ-MOLINA, Gabriela; VALIM, Valeria; TREVISANI, Virginia Fernandes Moca; PASOTO, Sandra G.; ACAR-DENIZLI, Nihan; ZEHER, Margit; SIVILS, Kathy; MANDL, Thomas; SEROR, Raphaele; LI, Xiaomei; BALDINI, Chiara; MARIETTE, Xavier; GOTTENBERG, Jacques-Ericn; DANDA, Debashish; PRIORI, Roberta; QUARTUCCIO, Luca; ARMAGAN, Berkan; KRUIZE, Aike A.; KWOK, Seung-Ki; WAHREN-HERLENIUS, Marie; PRAPROTNIK, Sonja; SENE, Damien; BARTOLONI, Elena; RISCHMUELLER, Maureen; SOLANS, Roser; SUZUKI, Yasunori; ISENBERG, David; WILAND, Piotr; NORDMARK, Gunnel; FRAILE, Guadalupe; BOOTSMA, Hendrika; NAKAMURA, Takashi; GIACOMELLI, Roberto; DEVAUCHELLE-PENSEC, Valerie; HOFAUER, Benedikt; BOMBARDIERI, Michele; HAMMENFORS, Daniel; CARSONS, Steven E.; GHEITA, Tamer A.; ATZENI, Fabiola; MOREL, Jacques; VOLLENVEIDER, Cristina; RAMOS-CASALS, Manuel; BRITO-ZERON, Pilar
  • conferenceObject
    SHORT AND LONG-TERM FOLLOW-UP OF PERIPHERAL NEUROPATHY DUE TO SYSTEMIC LUPUS ERYTHEMATOSUS: EVIDENCE OF A FAVORABLE OUTCOME
    (2018) FARGETTI, S.; BONFA, E.; SHINJO, S. K.; PASOTO, S. G.; SEGURO, L. P. C.; LOPES, M. R. U.; GONCALVES, C. R.; BORBA, E. F.
  • article 1 Citação(ões) na Scopus
    Short-term Accrual 2019 European League Against Rheumatism/American College of Rheumatology Domains and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage in Lupus Patients With and Without Nephritis at Disease Onset
    (2023) MUNHOZ, Gabriela A.; AIKAWA, Nadia E.; SILVA, Clovis A.; PASOTO, Sandra G.; PEDROSA, Tatiana N.; SEGURO, Luciana P. C.; BONFA, Eloisa; BORBA, Eduardo F.
    ObjectiveTo determine in a historical inception cohort the impact of lupus nephritis at disease onset in short-term accrual 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) domains. The possible association with treatment and damage was also investigated.MethodsOne hundred thirty-three consecutive adult systemic lupus erythematosus patients according to the 2019 EULAR/ACR criteria were divided according to the presence (RENAL-lupus) or absence of renal involvement (NONRENAL-lupus) at disease onset. The 2019 EULAR/ACR score and Systemic Lupus International Collaborating Clinics/ACR (SDI) were longitudinally evaluated over 3 years.ResultsRENAL-lupus (n = 49 [36.8%]) and NONRENAL-lupus (n = 84 [63.2%]) were similar regarding age (p = 0.704), female sex (p = 0.313), and black race (p = 0.506). At study entry, RENAL-lupus had higher 2019 EULAR/ACR total domains (30 [12-42] vs. 22 [10-36], p < 0.001) and used more often glucocorticoid (p < 0.001), mycophenolate mofetil (p = 0.007), and cyclophosphamide (p = 0.001). After 3 years, a stable number of domain scores was observed for the RENAL-lupus (30 [12-42] vs. 30 [12-42], p = 0.125), whereas an increase was observed for the NONRENAL-lupus (22 [10-36] vs. 23 [10-40], p < 0.001) compared with baseline. Accordingly, RENAL-lupus patients had a lower frequency of additional domains (3/49 [6.1%] vs. 37/84 [44.0%], p < 0.0001). New kidney involvement occurred in 15 (44.1%) of 34 patients of the NONRENAL-lupus. Both groups evolved with a comparable increase in frequency of patients with damage (SDI >= 1) at the end of the study (23/49 [46.9%] vs. 34/89 [40.54%], p = 0.585) with a similar median of SDI (1 [0-4] vs. 0 [0-2], p = 0.132).ConclusionsThe distinct pattern of accrual 2019 EULAR/ACR domains in patients with and without nephritis at disease onset suggests that close surveillance for additional organ involvement, including kidney, is mandatory in NONRENAL lupus in the first 3 years of disease. The unexpected comparable early damage in both groups despite milder disease and less intense immunosuppression in NONRENAL lupus reinforces the need for new and tailored therapies for these patients.
  • conferenceObject
    HOW DIFFERENT SYSTEMIC ORGAN INVOLVEMENTS OVERLAP IN PATIENTS WITH PRIMARY SJOGREN SYNDROME: ANALYSIS USING A MATHEMATICAL MODEL
    (2018) RETAMOZO, Soledad; HERNANDEZ-MOLINA, Gabriela; VALIM, Valeria; TREVISANI, Virginia Fernandes Moca; PASOTO, Sandra G.; ACAR-DENIZLI, Nihan; ZEHER, Margit; SIVILS, Kathy; MANDL, Thomas; SEROR, Raphaele; LI, Xiaomei; BALDINI, Chiara; MARIETTE, Xavier; GOTTENBERG, Jacques-Ericn; DANDA, Debashish; PRIORI, Roberta; QUARTUCCIO, Luca; ARMAGAN, Berkan; KRUIZE, Aike A.; KWOK, Seung-Ki; WAHREN-HERLENIUS, Marie; PRAPROTNIK, Sonja; SENE, Damien; BARTOLONI, Elena; RISCHMUELLER, Maureen; SOLANS, Roser; SUZUKI, Yasunori; ISENBERG, David; WILAND, Piotr; NORDMARK, Gunnel; FRAILE, Guadalupe; BOOTSMA, Hendrika; NAKAMURA, Takashi; GIACOMELLI, Roberto; DEVAUCHELLE-PENSEC, Valerie; HOFAUER, Benedikt; BOMBARDIERI, Michele; HAMMENFORS, Daniel; CARSONS, Steven E.; GHEITA, Tamer A.; ATZENI, Fabiola; MOREL, Jacques; VOLLENVEIDER, Cristina; RAMOS-CASALS, Manuel; BRITO-ZERON, Pilar
  • conferenceObject
    CLINICAL AND IMMUNOLOGICAL PRIMARY SJOGREN SYNDROME' DISEASE PATTERNS ARE DRIVEN BY GENDER AND AGE AT DIAGNOSIS
    (2018) RETAMOZO, Soledad; HERNANDEZ-MOLINA, Gabriela; VALIM, Valeria; TREVISANI, Virginia Fernandes Moca; PASOTO, Sandra G.; ACAR-DENIZLI, Nihan; ZEHER, Margit; SIVILS, Kathy; MANDL, Thomas; SEROR, Raphaele; LI, Xiaomei; BALDINI, Chiara; MARIETTE, Xavier; GOTTENBERG, Jacques-Ericn; DANDA, Debashish; PRIORI, Roberta; QUARTUCCIO, Luca; ARMAGAN, Berkan; KRUIZE, Aike A.; KWOK, Seung-Ki; WAHREN-HERLENIUS, Marie; PRAPROTNIK, Sonja; SENE, Damien; BARTOLONI, Elena; RISCHMUELLER, Maureen; SOLANS, Roser; SUZUKI, Yasunori; ISENBERG, David; WILAND, Piotr; NORDMARK, Gunnel; FRAILE, Guadalupe; BOOTSMA, Hendrika; NAKAMURA, Takashi; GIACOMELLI, Roberto; DEVAUCHELLE-PENSEC, Valerie; HOFAUER, Benedikt; BOMBARDIERI, Michele; HAMMENFORS, Daniel; CARSONS, Steven E.; GHEITA, Tamer A.; ATZENI, Fabiola; MOREL, Jacques; VOLLENVEIDER, Cristina; RAMOS-CASALS, Manuel; BRITO-ZERON, Pilar
  • article 12 Citação(ões) na Scopus
    Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy Bimodal Pattern of Onset and Treatment Response
    (2021) FARGETTI, Simone; UGOLINI-LOPES, Michelle R.; PASOTO, Sandra G.; SEGURO, Luciana P. C.; SHINJO, Samuel K.; BONFA, Eloisa; BORBA, Eduardo F.
    Background/Objective: Our aim was to describe the short- and long-term outcome of peripheral neuropathy (PN) attributed exclusively to systemic lupus erythematosus (SLE). Methods: Systemic lupus erythematosus patients with defined PN (clinical and electroneuromyography) were retrospectively evaluated at onset, 1-year, and 5-year follow-up using a standardized electronic chart database that started in 2000. Exclusion criteria were comorbidities, drugs, and infections. Age-, sex-, and disease duration-matched SLE patients without PN were selected as controls. Results: Lupus PN was identified in 38 (1.8%) of 2074 patients, and almost two thirds had PN onset in the first 5 years of SLE (63.2%). Peripheral neuropathy SLE had higher frequencies of cutaneous vasculitis (50% vs 21.1%, p = 0.002), lymphopenia (60.5% vs 36.8%, p = 0.027), anti-Sm (52.6% vs 27.6%, p = 0.013), and higher SLEDAI-2K scores (11.5 +/- 10.5 vs 4.9 +/- 6.7, p < 0.001) compared with controls. The most common type was polyneuropathy (71.1%) with sensory-motor pattern (68.4%). At PN diagnosis, all patients received glucocorticoid and 97.4% started immunosuppressive therapy (50% intravenous cyclophosphamide, 42.1% azathioprine). After 1-year follow-up, 92.1% had a favorable outcome with complete (36.8%) or partial remission (55.2%), in parallel with a decrease in prednisone dose (48.3 +/- 17.9 vs 15.3 +/- 13.4 mg/d, p < 0.001), symptomatic therapy (57.9% vs 29.7%, p = 0.02), and SLEDAI-2K score (11.5 +/- 10.5 vs 1.7 +/- 3.7, p < 0.001). SLEDAI-2K scores were higher in patientswho had PN onsetwith less than 1 year of SLE duration, compared with those with more than 5 years of disease (21.3 +/- 9.1 vs 3.9 +/- 5.3, p < 0.001). Early-PN-onset group had a better response to treatment (complete remission at 1-year follow-up 61.5% vs 25%, p = 0.039). At 5-year follow-up, 89.3% remained with complete/partial remission. Conclusions: Peripheral neuropathy attributed to SLE itself is a rare manifestation with a bimodal pattern, characterized by a predominant early-onset group associated with high disease activity and a higher rate of complete remission, and a late-onset group with low disease activity and a partial therapy response.
  • article 0 Citação(ões) na Scopus
    Longitudinal Extensive Transverse Myelitis and Central Diabetes Insipidus: A Severe Flare of Systemic Lupus Erythematosus
    (2017) DEVEZA, Leticia Miranda Alle; NEVES, Emily Figueiredo Vieira; SEGURO, Luciana Parente Costa; PEREIRA, Samira Luisa dos Apostolos; BONFA, Eloisa; PASOTO, Sandra Gofinet
  • article 18 Citação(ões) na Scopus
    Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment A Narrative Review of Literature for Clinical Practice
    (2021) YUKI, Emily Figueiredo Neves; SILVA, Clovis A.; AIKAWA, Nadia E.; ROMITI, Ricardo; HEISE, Carlos Otto; BONFA, Eloisa; PASOTO, Sandra Gofinet
    Background: Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE). Recently, lenalidomide has been also prescribed for SLE/CLE treatment. Literature regarding efficacy/adverse events for these drugs is scarce with a single systematic review and meta-analysis focused solely on thalidomide for refractory cutaneous lupus subtypes. Objective: We, therefore, addressed in this narrative review the efficacy/adverse effects of thalidomide and lenalidomide for SLE and CLE. In addition, we provide a specialist approach for clinical practice based on the available evidence. Results: Efficacy of thalidomide for refractory cutaneous lupus treatment was demonstrated by several studies, mostly retrospective with small sample size(<= 20). The frequency of peripheral polyneuropathy is controversial varying from 15-80% with no consistent data regarding cumulative dose and length of use. Drug withdrawn results in clinical partial/complete reversibility for most cases (70%). For lenalidomide, seven studies (small sample sizes) reported its efficacy for SLE/CLE with complete/partial response in all patients with a mean time to response of 3 months. Flare rate varied from 25-75% occurring 0.5-10 months after drug withdrawn. There were no reports of polyneuropathy/worsening of previous thalidomide-induced neuropathy, but most of them did not perform nerve conduction studies. Teratogenicity risk exist for both drugs and strict precautions are required. Conclusions: Thalidomide is very efficacious as an induction therapy for patients with severe/refractory cutaneous lupus with high risk of scarring, but its longstanding use should be avoided due to neurotoxicity. Lenalidomide is a promising drug for skin lupus treatment, particularly regarding the apparent lower frequency of nerve side effects.